0001562180-18-002884.txt : 20180605 0001562180-18-002884.hdr.sgml : 20180605 20180605174020 ACCESSION NUMBER: 0001562180-18-002884 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180601 FILED AS OF DATE: 20180605 DATE AS OF CHANGE: 20180605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HAYDEN DONALD J JR CENTRAL INDEX KEY: 0001202285 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37553 FILM NUMBER: 18882338 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENXBIO Inc. CENTRAL INDEX KEY: 0001590877 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471851754 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9600 BLACKWELL ROAD STREET 2: SUITE 210 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-552-8181 MAIL ADDRESS: STREET 1: 9600 BLACKWELL ROAD STREET 2: SUITE 210 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: REGENXBIO, Inc. DATE OF NAME CHANGE: 20150116 FORMER COMPANY: FORMER CONFORMED NAME: ReGenX Biosciences, LLC DATE OF NAME CHANGE: 20131101 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2018-06-01 false 0001590877 REGENXBIO Inc. RGNX 0001202285 HAYDEN DONALD J JR C/O REGENXBIO INC. 9600 BLACKWELL ROAD, SUITE 210 ROCKVILLE MD 20850 true false false false Common Stock 2018-06-01 4 M false 100.00 0.85 A 100.00 D Common Stock 2018-06-01 4 S false 100.00 55.00 D 0.00 D Common Stock 2018-06-05 4 M false 14900.00 0.85 A 14900.00 D Common Stock 2018-06-05 4 S false 14900.00 55.01 D 0.00 D Stock Option (Right to Buy) 0.85 2018-06-01 4 M false 100.00 0.00 D 2024-09-23 Common Stock 100.00 204000.00 D Stock Option (Right to Buy) 0.85 2018-06-05 4 M false 14900.00 0.00 D 2024-09-23 Common Stock 14900.00 189100.00 D This transaction was effected pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $55.00 to $55.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares shall vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. /s/ Patrick J. Christmas as attorney-in-fact 2018-06-05